Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GRN | P28799 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574076 | 0.80 | RAB9A (0.42) | KDM4EPOLBLMNA | |
| SCHEMBL16055493 | 0.79 | KDM4E (0.34) | KDM4EGRNSORT1POLB | |
| SCHEMBL4424874 | 0.78 | LRRK2 (0.41) | KDM4EGRNSORT1 | |
| SCHEMBL1257733 | 0.78 | KDM4E (0.36) | KDM4EGRNSORT1MAPK14 | |
| SCHEMBL26341502 | 0.77 | LRRK2 (0.39) | KDM4EGRNSORT1 | |
| SCHEMBL4420775 | 0.77 | KDM4E (0.46) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL711746 | 0.76 | KDM4E (0.49) | KDM4EGRNSORT1POLBMAPK14 | |
| SCHEMBL422069 | 0.74 | KDM4E (0.52) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL821308 | 0.74 | KDM4E (0.52) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL283910 | 0.74 | KDM4E (0.44) | KDM4EGRNSORT1POLBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | claimed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | claimed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | claimed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | claimed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| EP-2081905-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2009-07-29 | — | — | EP | claimed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | claimed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | claimed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2008014199-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-31 | — | — | WO | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| EP-4747242-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2026-05-27 | — | — | EP | disclosed |
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-05 | — | — | US | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6099592-A | SPECIFIED 3-SUBSTITUTED 4,5-DIAMINOPYRAZOLES SUCH AS 1-BENZYL-4,5-DIAMINO-3-METHYLPYRAZOLE AS OXIDATION DYE PRECURSORS; USE TO OBTAIN DYE COMPOSITIONS LEADING TO STRONG COLORATIONS, IN SHADES RANGING FROM RED TO BLUE | L'OREAL (FR) | 2000-08-08 | — | — | US | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | DDR1, DDR2, DDRGK1 | KDM4E 3343/4885GRN 1294/4885SORT1 4087/4885 |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KDM4E 3926/4885GRN 4069/4885SORT1 4400/4885 |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | KDM4E 3080/4885GRN 1912/4885SORT1 3038/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | KDM4E 1224/4885GRN 4678/4885SORT1 3142/4885 |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KDM4E 3448/4885GRN 4524/4885SORT1 4451/4885 |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | KDM4E 2422/4885GRN 4459/4885SORT1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.